[18F]FET-PET imaging for treatment and response monitoring of radiation therapy in malignant glioma patients - A review

Frontiers in Oncology

Volumn 3 APR, Issue , 2013, Pages

  Gotz I ^a   Grosu, A L ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Glioblastoma multiforme; Monitoring; Mri imaging; Pet ct; Radiation therapy

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; 3' FLUOROTHYMIDINE; FLUORODEOXYGLUCOSE F 18; KI 67 ANTIGEN; LEVODOPA; METHIONINE; THYMIDINE KINASE;

BRAIN TUMOR; CELL PROLIFERATION; CLINICAL PRACTICE; COMPUTER ASSISTED TOMOGRAPHY; FOLLOW UP; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GLIOBLASTOMA; HUMAN; IMAGE GUIDED RADIOTHERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; SHORT SURVEY; TREATMENT PLANNING; TREATMENT RESPONSE; TUMOR DIFFERENTIATION; TUMOR GROWTH;

EID: 84886387787     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2013.00104     Document Type: Short Survey

References (39)

1. Astner, S. T., Grosu, A. L., Weber, W. A., Wester, H. J., Schwaiger, M., and Molls, M. (2005). O-(2-(18F)fluorethyl)-L-tyrosine compared to L-(methyl-11C)methionine in positron emission tomography for tumor volume delineation of gliomas and metastases. Int. J. Radiat. Oncol. Biol. Phys. 2005, S65.
2. Becherer, A., Karanikas, G., Szabo, M., Zettinig, G., Asenbaum, S., Marosi, C., et al. (2003). Brain tumour imaging with PET: a comparison between [18F]fluorodopa and [11C]methionine. Eur. J. Nucl. Med. Mol. Imaging 30, 1561-1567.
3. Brandsma, D., and van den Bent, M. J. (2009). Pseudoprogression and pseudoresponse in the treatment of gliomas. Curr. Opin. Neurol. 22, 633-638.
4. Chen, W., Cloughesy, T., Kamdar, N., Satyamurthy, N., Bergsneider, M., Liau, L., et al. (2005). Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG. J. Nucl. Med. 46, 945-952.
5. Cher, L. M., Murone, C., Lawrentschuk, N., Ramdave, S., Papenfuss, A., Hannah, A., et al. (2006). Correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in gliomas using 18F-fluoromisonidazole, 18F-FDG PET, and immunohistochemical studies. J. Nucl. Med. 47, 410-418.
6. Derlon, J. M., Bourdet, C., Bustany, P., Chatel, M., Theron, J., Darcel, F., et al. (1989). [11C]L-methionine uptake in gliomas. Neurosurgery 25, 720-728.
7. Dhermain, F. G., Hau, P., Lanfermann, H., Jacobs, A. H., and van den Bent, M. J. (2010). Advanced MRI and PET imaging for assessment of treatment response in patients with gliomas. Lancet Neurol. 9, 906-920.
8. Giglio, P., and Gilbert, M. R. (2003). Cerebral radiation necrosis. Neurologist 9, 180-188.
9. Grosu, A. L., Astner, S. T., Riedel, E., Nieder, C., Wiedenmann, N., Heinemann, F., et al. (2011). An interindividual comparison of O-(2-[(18)F]fluoroethyl)-L-tyrosine (FET)-and L-[methyl-(11)C]methionine (MET)-PET in patients with brain gliomas and metastases. Int. J. Radiat. Oncol. Biol. Phys. 81, 1049-1058.
10. Grosu, A. L., Weber, W. A., Riedel, E., Jeremic, B., Nieder, C., Franz, M., et al. (2005a). L-(methyl-11C) methionine positron emission tomography for target delineation in resected high-grade gliomas before radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 63, 64-74.
11. Grosu, A. L., Weber, W. A., Franz, M., Stark, S., Piert, M., Thamm, R., et al. (2005b). Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 63, 511-519.
12. Hein, P. A., Eskey, C. J., Dunn, J. F., and Hug, E. B. (2004). Diffusion-weighted imaging in the follow-up of treated high-grade gliomas: tumor recurrence versus radiation injury. AJNR Am. J. Neuroradiol. 25, 201-209.
13. Heiss, P., Mayer, S., Herz, M., Wester, H. J., Schwaiger, M., and Senekowitsch-Schmidtke, R. (1999). Investigation of transport mechanism and uptake kinetics of O-(2-[18F]fluoroethyl)-L-tyrosine in vitro and in vivo. J. Nucl. Med. 40, 1367-1373.
14. Hermanto, U., Frija, E. K., Lii, M. J., Chang, E. L., Mahajan, A., and Woo, S. Y. (2007). Intensity-modulated radiotherapy (IMRT) and conventional three-dimensional conformal radiotherapy for high-grade gliomas: does IMRT increase the integral dose to normal brain? Int. J. Radiat. Oncol. Biol. Phys. 67, 1135-1144.
15. Hoffman, J. M., Waskin, H. A., Schifter, T., Hanson, M. W., Gray, L., Rosenfeld, S., et al. (1993). FDG-PET in differentiating lymphoma from nonmalignant central nervous system lesions in patients with AIDS. J. Nucl. Med. 34, 567-575.
16. Jacobs, A. H., Kracht, L. W., Gossmann, A., Ruger, M. A., Thomas, A. V., Thiel, A., et al. (2005). Imaging in neurooncology. NeuroRx 2, 333-347.
17. Judenhofer, M. S., Wehrl, H. F., Newport, D. F., Catana, C., Siegel, S. B., Becker, M., et al. (2008). Simultaneous PET-MRI: a new approach for functional and morphological imaging. Nat. Med. 14, 459-465.
18. Kasenda, B., Haug, V., Schorb, E., Fritsch, K., Finke, J., Mix, M., et al. (2013). 18F-FDG PET is an independent outcome predictor in primary central nervous system lymphoma. J. Nucl. Med. 54, 184-191.
19. Langleben, D. D., and Segall, G. M. (2000). PET in differentiation of recurrent brain tumor from radiation injury. J. Nucl. Med. 41, 1861-1867.
20. Milker-Zabel, S., Zabel-du Bois, A., Henze, M., Huber, P., Schulz-Ertner, D., Hoess, A., et al. (2006). Improved target volume definition for fractionated stereotactic radiotherapy in patients with intracranial meningiomas by correlation of CT, MRI, and [68Ga]-DOTATOC-PET. Int. J. Radiat. Oncol. Biol. Phys. 65, 222-227.
21. Miyagawa, T., Oku, T., Uehara, H., Desai, R., Beattie, B., Tjuvajev, J., et al. (1998). "Facilitated" amino acid transport is upregulated in brain tumors. J. Cereb. Blood Flow Metab. 18, 500-509.
22. Mullins, M. E., Barest, G. D., Schaefer, P. W., Hochberg, F. H., Gonzalez, R. G., and Lev, M. H. (2005). Radiation necrosis versus glioma recurrence: conventional MR imaging clues to diagnosis. AJNR Am. J. Neuroradiol. 26, 1967-1972.
23. Narayana, A., Yamada, J., Berry, S., Shah, P., Hunt, M., Gutin, P. H., et al. (2006). Intensity-modulated radiotherapy in high-grade gliomas: clinical and dosimetric results. Int. J. Radiat. Oncol. Biol. Phys. 64, 892-897.
24. Nariai, T., Tanaka, Y., Wakimoto, H., Aoyagi, M., Tamaki, M., Ishiwata, K., et al. (2005). Usefulness of L-[methyl-11C] methionine-positron emission tomography as a biological monitoring tool in the treatment of glioma. J. Neurosurg. 103, 498-507.
25. Pauleit, D., Floeth, F., Hamacher, K., Riemenschneider, M. J., Reifenberger, G., Muller, H. W., et al. (2005). O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas. Brain 128(Pt 3), 678-687.
26. Piroth, M. D., Pinkawa, M., Holy, R., Klotz, J., Nussen, S., Stoffels, G., et al. (2011). Prognostic value of early [18F]fluoroethyltyrosine positron emission tomography after radiochemotherapy in glioblastoma multiforme. Int. J. Radiat. Oncol. Biol. Phys. 80, 176-184.
27. Popperl, G., Goldbrunner, R., Gildehaus, F. J., Kreth, F. W., Tanner, P., Holtmannspotter, M., et al. (2005). O-(2-[18F]fluoroethyl)-L-tyrosine PET for monitoring the effects of convection-enhanced delivery of paclitaxel in patients with recurrent glioblastoma. Eur. J. Nucl. Med. Mol. Imaging 32, 1018-1025.
28. Popperl, G., Kreth, F. W., Mehrkens, J. H., Herms, J., Seelos, K., Koch, W., et al. (2007). FET PET for the evaluation of untreated gliomas: correlation of FET uptake and uptake kinetics with tumour grading. Eur. J. Nucl. Med. Mol. Imaging 34, 1933-1942.
29. Rachinger, W., Goetz, C., Pöpperl, G., Gildehaus, F. J., Kreth, F. W., Holtmannspötter, M., et al. (2005). Positron emission tomography with O-(2-[18F]fluoroethyl)-L-tyrosine versus magnetic resonance imaging in the diagnosis of recurrent gliomas. Neurosurgery 57, 505-511.
30. Rock, J. P., Scarpace, L., Hearshen, D., Gutierrez, J., Fisher, J. L., Rosenblum, M., et al. (2004). Associations among magnetic resonance spectroscopy, apparent diffusion coefficients, and image-guided histopathology with special attention to radiation necrosis. Neurosurgery 54, 1111-1117; discussion 7-9.
31. Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J., et al. (2005). Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352, 987-996.
32. Taal, W., Brandsma, D., de Bruin, H. G., Bromberg, J. E., Swaak-Kragten, A. T., Smitt, P. A., et al. (2008). Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide. Cancer 113, 405-410.
33. Terakawa, Y., Tsuyuguchi, N., Iwai, Y., Yamanaka, K., Higashiyama, S., Takami, T., et al. (2008). Diagnostic accuracy of 11C-methionine PET for differentiation of recurrent brain tumors from radiation necrosis after radiotherapy. J. Nucl. Med. 49, 694-699.
34. Tripathi, M., Sharma, R., Varshney, R., Jaimini, A., Jain, J., Souza, M. M., et al. (2012). Comparison of F-18 FDG and C-11 methionine PET/CT for the evaluation of recurrent primary brain tumors. Clin. Nucl. Med. 37, 158-163.
35. Tsuyuguchi, N., Takami, T., Sunada, I., Iwai, Y., Yamanaka, K., Tanaka, K., et al. (2004). Methionine positron emission tomography for differentiation of recurrent brain tumor and radiation necrosis after stereotactic radiosurgery-in malignant glioma. Ann. Nucl. Med. 18, 291-296.
36. Ullrich, R., Backes, H., Li, H., Kracht, L., Miletic, H., Kesper, K., et al. (2008). Glioma proliferation as assessed by 3'-fluoro-3'-deoxy-L-thymidine positron emission tomography in patients with newly diagnosed high-grade glioma. Clin. Cancer Res. 14, 2049-2055.
37. Vander Borght, T., Asenbaum, S., Bartenstein, P., Halldin, C., Kapucu, O., Van Laere, K., et al. (2006). EANM procedure guidelines for brain tumour imaging using labelled amino acid analogues. Eur. J. Nucl. Med. Mol. Imaging 33, 1374-1380.
38. Weber, W. A., Wester, H. J., Grosu, A. L., Herz, M., Dzewas, B., Feldmann, H. J., et al. (2000). O-(2-[18F]fluoroethyl)-L-tyrosine and L-[methyl-11C]methionine uptake in brain tumours: initial results of a comparative study. Eur. J. Nucl. Med. 27, 542-549.
39. Wen, P. Y., Macdonald, D. R., Reardon, D. A., Cloughesy, T. F., Sorensen, A. G., Galanis, E., et al. (2010). Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J. Clin. Oncol. 28, 1963-1972.